Bangkok Genomics Innovation PCL (BKK:BKGI) Current Deferred Revenue: ฿11.8 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BKK:BKGI Bangkok Genomics Innovation PCL BKK:BKGI
45 GF Score
Price ฿2.38
! 11 Warning Signs
View Full Analysis

What is Bangkok Genomics Innovation PCL Current Deferred Revenue?

Bangkok Genomics Innovation PCL BKK:BKGI 45 Current Deferred Revenue is ฿11.8 Mil as of Jun. 2026. GuruFocus rates BKK:BKGI with a GF Score™ of 45/100. The stock has 11 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Bangkok Genomics Innovation PCL's current deferred revenue for the quarter that ended in Jun. 2026 was ฿11.8 Mil.

Bangkok Genomics Innovation PCL Current Deferred Revenue Related Terms

Bangkok Genomics Innovation PCL Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Bangkok Genomics Innovation PCL's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bangkok Genomics Innovation PCL Current Deferred Revenue Chart

Bangkok Genomics Innovation PCL Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial 0.42 1.94 9.32 5.28 13.15

Bangkok Genomics Innovation PCL Semi-Annual Data
Dec19 Dec20 Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 4.62 5.28 3.65 13.15 11.85
BKK:BKGI
45GF Score
Bangkok Genomics Innovation PCL BKK:BKGI
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of ฿11.8 Mil mean?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a Current Deferred Revenue of ฿11.8 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Bangkok Genomics Innovation PCL and its competitors.
Is Bangkok Genomics Innovation PCL's Current Deferred Revenue too high?
Bangkok Genomics Innovation PCL's current Current Deferred Revenue is ฿11.8 Mil. Overall, Bangkok Genomics Innovation PCL has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Genomics Innovation PCL's Current Deferred Revenue compare to TMO and DHR?
Bangkok Genomics Innovation PCL's Current Deferred Revenue of ฿11.8 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Diagnostics & Research company?
A good Current Deferred Revenue depends on the Medical Diagnostics & Research industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Bangkok Genomics Innovation PCL and its competitors. Bangkok Genomics Innovation PCL's current Current Deferred Revenue is ฿11.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Genomics Innovation PCL stock overvalued right now?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a current Current Deferred Revenue of ฿11.8 Mil. The current Current Deferred Revenue is ฿11.8 Mil. Bangkok Genomics Innovation PCL's overall GF Score™ is 45/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Bangkok Genomics Innovation PCL (BKK:BKGI), the current Current Deferred Revenue is ฿11.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bangkok Genomics Innovation PCL Business Description

Address 3689 Rama 4 Road, Phra Khanong Subdistrict, Khlong Toei Subdistrict, Bangkok, THA, 10110
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
45GF Score

Get the complete analysis for BKK:BKGI

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿2.38
Price